Press release
Cerbomed at the 4th International Epilepsy Colloquium in Marburg
About NEMOS
NEMOS is the world’s first t-VNS device and is intended for people suffering from various difficult to treat neurological and psychiatric diseases. The current lead indications are drug-resistant epilepsies. NEMOS consists of a stimulation unit and an ear electrode which the patient wears like an earphone for 3 to 5 hours per day.
Cerbomed’s t-VNS therapy uses the fact that a branch of the vagus nerve is located directly under the skin in areas of the outer ear and that nerves can be stimulated through the skin (transcutaneously) with electrical impulses.
Cerbomed expects t-VNS to offer a highly attractive and cost-effective alternative to current and emerging VNS treatments, other neurostimulation methods, surgery or pharmacologic therapies. These therapeutic alternatives are connected either with higher risks or have undesirable side effects.
Cerbomed is a privately held medical device company based in Erlangen, Germany, aiming to become the leader for the development of non-invasive Vagus Nerve Stimulation (VNS) therapies. The company was founded in 2005 to develop and commercialize its proprietary, transcutaneous Vagus Nerve Stimulation (t-VNS) technology and devices for therapeutic uses. NEMOS products comprise the world’s first non-invasive VNS device enabling specific electrical brain stimulation. The company has received a CE-mark for NEMOS in Europe.
cerbomed GmbH
Dr. Martin Hyca, Director Marketing
Henkestrasse 91
DE-91052 Erlangen
+49 9131 9202 76 30
martin.hyca@cerbomed.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Cerbomed at the 4th International Epilepsy Colloquium in Marburg here
News-ID: 180984 • Views: …
More Releases from cerbomed GmbH
Pharmaceuticals and medical technology will go hand in hand in future – DESITI …
ERLANGEN/HAMBURG, September 17th, 2015 – The medical technology company cerbomed GmbH from Erlangen and the pharmaceutical company DESITIN Arzneimittel GmbH from Hamburg have entered into a groundbreaking distribution agreement: DESITIN has been granted exclusive distribution rights in Germany by cerbomed for the transcutaneous vagus nerve stimulator NEMOS for treatment of epilepsy.
The successful medium-sized independent company DESITIN has been a specialist provider and proficient partner to doctors and patients in the…
transcutaneous Vagus Nerve Stimulation for epilepsies now available in Norway
ERLANGEN/DRAMMEN, May 28th, 2015 – To address the Norwegian market with transcutaneous Vagus Nerve Stimulation (t-VNS), the medical device company cerbomed from Erlangen, Germany, is cooperating with an experienced distribution partner: Scan-Med A/S from Drammen, Norway.
The company, founded in 1982, considers itself as a connecting link between manufacturers of medical devices and hospitals, as well as health institutions and specialized on distribution service and support of medical equipment.
“We are…
Vagus nerve stimulation without surgery now available in Denmark, Finland and Sw …
ERLANGEN/AALBORG, Mai 28th, 2015 – More than 30 percent of all epilepsy patients still suffer from continued occurrence of seizures, despite appropriate treatment with anticonvulsive drugs. For these patients, only few treatment alternatives are available at the moment. One promising therapy option is transcutaneous Vagus Nerve Stimulation (t-VNS), now also available for patients in Denmark, Sweden and Finland. This has been made possible by cerbomed‘s new distributor Cephalon A/S.…
Trial results for transcutaneous Vagus Nerve Stimulation in pharmacoresistant ep …
ERLANGEN/DRESDEN, 30th April 2015 – At the 9th annual joint conference of the three German-speaking regions of the International League Against Epilepsy in Dresden, the results of a trial on transcutaneous Vagus Nerve Stimulation (t-VNS) in pharmacoresistant epilepsy were presented for the first time.
Trial shows reduction in seizures with t-VNS
In the multi-centre, randomised, controlled, 2-arm, double-blind study, 76 adult epilepsy patients from Germany and Austria were treated over 5…
More Releases for VNS
External VNS Device Market Size, Share and Growth Report, 2034
On May 9, 2025, Exactitude Consultancy., Ltd. released a research report titled "External VNS Device Market". This report covers the global External VNS Device market sales, sales volume, price, market share, ranking of major companies, etc., and provides a detailed analysis by region, country, product type, and application. It also forecasts the market size of automotive kick sensors based on market patterns from 2020 to 2034 and future market trends.…
American MSB VNS Ltd. Announces Global Market Expansion
Large-Scale Entry into Asia and Africa
California, United States - June 21, 2024 - American MSB VNS Ltd (VNS) is pleased to announce that the company will expand into Asia and Africa on a large scale. As an innovation-driven Internet advertising company, VNS is committed to providing excellent advertising promotion services through its system service platform in cooperation with the world's top online shopping malls and social platforms.
Company Profile and Business…
Global External VNS Devices Market is projected to reach the value of $449.92 Mi …
According to the report published by Virtue Market Research in 2022, the Global External VNS Devices Market was valued at $225.8 billion, and is projected to reach a market size of $449.92 Million by 2030. Over the forecast period of 2023-2030, market is projected to grow at a CAGR of 9%.
Read More @ https://virtuemarketresearch.com/report/external-vns-devices-market
In the realm of healthcare technology, External Vagus Nerve Stimulation (VNS) devices have emerged as a transformative…
Vagus Nerve Stimulation (VNS) Market Trends, Size, Share, Company Overview, Grow …
Global Vagus Nerve Stimulation (VNS) Market Analysis 2026 Report provides strategists, marketers and senior management with the critical information they need to assess the global Vagus Nerve Stimulation (VNS) Market as it emerges from the Covid-19 shut down. The impact of Coronavirus (COVID-19) on global market has reinforced many trends already shaping the industry pre COVID-19, There is a long-term trend towards the repositioning of players as entertainment providers on…
Vagus Nerve Stimulation (VNS) Devices Market Latest Innovations, Drivers and Ind …
Precision Business Insights published a research report on “Vagus Nerve Stimulation (VNS) Devices Market by Product Type (Implantable VNS Devices and External VNS Devices), By Application (Depression, Epilepsy, and Migraine), By End User (Hospitals, Ambulatory Surgical Centers (ASCS), and Others), and Geography- Global/Region/Country Forecast to 2028”. Global vagus nerve stimulation (VNS) devices market was valued at US$ XX Mn in the year 2020 and anticipated to reach at XX%…
Vagus Nerve Stimulation (VNS) Devices Market to Witness Robust Expansion by 2024
LP INFORMATION offers a latest published report on Vagus Nerve Stimulation (VNS) Devices Market Analysis and Forecast 2019-2024 delivering key insights and providing a competitive advantage to clients through a detailed report.
According to this study, over the next five years the Vagus Nerve Stimulation (VNS) Devices market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from…
